Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders

American Journal of Hematology

Volumn 89, Issue 3, 2014, Pages 346-347

  Ottone, Tiziana ^a,b   Hasan, Syed Khizer ^a,b   Voso, Maria Teresa ^c   Ledda, Antonio ^d   Montefusco, Enrico ^e   Fenu, Susanna ^f   Pagoni, Maria ^g   Hubmann, Maximillian ^h   Lunghi, Monia ⁱ   Platzbecker, Uwe ^j   Lo Coco, Francesco ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d Binaghi Hospital   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^g EVANGELISMOS HOSPITAL   (Greece)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^j UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA INTERFERON; CYTOTOXIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR; MITOXANTRONE; PROMYELOCYTIC LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR RUNX1;

BIOLOGICAL ACTIVITY; CHROMOSOME 15; CHROMOSOME BREAKAGE; DEMYELINATING NEUROPATHY; DNA CLEAVAGE; DNA SEQUENCE; GENETIC ANALYSIS; HUMAN; INTRON; LETTER; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RISK FACTOR; SEQUENCE ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHROMOSOME BREAKPOINTS; CHROMOSOMES, HUMAN, PAIR 15; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; ONCOGENE PROTEINS, FUSION; PROTEIN ISOFORMS; TOPOISOMERASE II INHIBITORS; TRANSLOCATION, GENETIC;

EID: 84896879047     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23646     Document Type: Letter

References (7)

1. Pulsoni A, Pagano L, Lo Coco F, et al. Clinico-biological features and outcome of acute promyelocytic leukemia occurring as a second tumor: The GIMEMA experience. Blood 2002;100:1972-1976.
2. Lo Coco F, Hasan SK, Montesinos P, et al. Biology and management of therapy-related acute promyelocytic leukemia. Curr Opin Oncol 2013;25:695-700.
3. Klimek VM. Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia. Curr Opin Hematol 2013;20:137-143.
4. Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005;352:1529-1538.
5. Hasan SK, Mays AN, Ottone T, et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008;112:3383-3390.
6. Ottone T, Hasan SK, Montefusco E, et al. Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation. Genes Chromosomes Cancer 2009;48:213-221.
7. Joannides M, Mays AN, Mistry AR, et al. Molecular pathogenesis of secondary acute promyelocytic leukemia. Mediterr J Hematol Infect Dis 2011;3:e2011045.